semaglutide nash phase 3 A Placebo-Controlled Trial of Subcutaneous in Nonalcoholic Steatohepatitis semaglutide nash phase 3 essence

There is a myth that all weight loss is good weight loss

Some doctors also offer patients GLP-1 formulations like semaglutide, which contain the same active ingredient as their corresponding prescribed drug but allow doctors to fine-tune dosing

Semaglutide is a GLP-1 receptor agonist that regulates blood glucose, slows gastric emptying, and reduces appetite

- Mean Platelet Volume* (MPV)

The SELECT trial (semaglutide, published 2023-2024) reported cardiovascular-event-reduction signals in research populations without prior metabolic-disease diagnosis

[DOI] [PMC free article] [PubMed] [Google Scholar] 40.Mundt JC, Greist JH, Jefferson JW, et al